title: [MMP-3 as a Biomarker of Disease Activity of Rheumatoid Arthritis].
abstract: The aim of this study was to confirm the clinical significance of serum MMP-3 measurement in the evalua- tion of disease activity and effectiveness of treatment in patients with rheumatoid arthritis (RA). MMP-3 was measured for 206 outpatients with RA during a period of 4 months, and also serially measured for RA patients treated with methotrexate(MTX) alone or together with infliximab (IFX). Serum MMP-3 was significantly correlated with CRP, SAA, and ESR. Significant correlation of serum MMP-3 was found not only with DAS28 (CRP) in female and male patients (p <0.0001 and p < 0.0051, respectively) but also with the EULAR classification criteria for the disease activity of RA. Among the items of DAS28(CRP), the strongest association of MMP-3 was found with swollen joint counts. Furthermore, MMP-3 levels increased with advances in Stage and Class of RA. MMP-3 levels gradually decreased 12 and 24 weeks after successful treatment with MTX (p=0.0188 and p=0.0179, respectively). Extent of the decrease was more prominent in patients with better response to MTX than in those with poor response. MMP-3 levels significantly decreased 6 weeks after IFX treatment and continued to decrease until 48 weeks. Significant decrease of MMP-3 level from before treatment was shown only in the good response group to IFX after 48 weeks of treatment. MMP-3 level was shown to be useful as a disease activity marker in RA patients. In addition, serial measurement of MMP-3 maybe helpful to evaluate the effect of treatments with MTX and IFX.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Uemura
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Hayashi
authors.forename: Toshio
authors.initials: T
authors.lastname: Takahashi
authors.forename: Toshiharu
authors.initials: T
authors.lastname: Saitho
authors.forename: Ryousuke
authors.initials: R
authors.lastname: Umeda
authors.forename: Yoshihide
authors.initials: Y
authors.lastname: Ichise
authors.forename: Sho
authors.initials: S
authors.lastname: Sendo
authors.forename: Goh
authors.initials: G
authors.lastname: Tsuji
authors.forename: Shunichi
authors.initials: S
authors.lastname: Kumagai
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001172:Arthritis, Rheumatoid / Q000175:diagnosis* / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism; D015415:Biomarkers / Q000097:blood*; D005260:Female; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use; D008297:Male; D019278:Matrix Metalloproteinase 3 / Q000378:metabolism*; D008875:Middle Aged; D010045:Outpatients; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D000069285:Infliximab; C511768:MMP3 protein, human; D019278:Matrix Metalloproteinase 3